Yahoo Poland Wyszukiwanie w Internecie

Search results

1. fusionpharma.comThe Evolution of Radiopharmaceuticals - Fusion Pharma - Home

   fusionpharma.com

   • Zapisane w pamięci cache

   We created a proprietary linker to connect cancer-seeking molecules and alpha emitting medical isotopes. The Fast-Clear™ linker was specifically engineered to improve the safety of radiopharmaceuticals by helping the drug clear from normal, healthy tissues.

   • About

     ABOUT FUSION. Next Generation. Radiation Therapy for Cancer....

   • Pipeline

     The Fusion Pipeline. FPI-2265. Fusion’s lead program,...

   • Technology

     Given the power and versatility of the Fast-Clear™ linker...

   • Careers

     Fusion Management. The faces behind Fusion Pharmaceuticals....

   • Fusion Leadership

     Before joining Fusion, he was Vice President of Development...

   • Advisory Board

     Dr. Khuntia is a board-certified radiation oncologist who...

2. www.astrazeneca.com › press-releases › 2024AstraZeneca to acquire Fusion to accelerate the development of...

   www.astrazeneca.com › press-releases › 2024

   • Zapisane w pamięci cache

   19 mar 2024 · AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).

3. fusionpharma.com › fusion-pipelinePipeline - Fusion Pharma

   fusionpharma.com › fusion-pipeline

   • Zapisane w pamięci cache

   The Fusion Pipeline. FPI-2265. Fusion’s lead program, FPI-2265, is evaluating 225 Ac-PSMA I&T, a small molecule targeting PSMA expressed in prostate cancers. The alpha-emitting radiopharmaceutical is being evaluated in the Phase 2 TATCIST trial.

4. www.astrazeneca.com › media-centre › press-releasesAcquisition of Fusion completed - AstraZeneca

   www.astrazeneca.com › media-centre › press-releases

   • Zapisane w pamięci cache

   4 cze 2024 · AstraZeneca today announced the successful completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).

5. ca.finance.yahoo.com › news › fusion-pharmaceuticals-acquired-astrazenecaFusion Pharmaceuticals to be Acquired by AstraZeneca,...

   ca.finance.yahoo.com › news › fusion-pharmaceuticals-acquired-astrazeneca

   • Zapisane w pamięci cache

   19 mar 2024 · Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced the Company...

6. www.prnewswire.com › news-releases › fusion-pharmaceuticals-to-be-acquired-by-astFusion Pharmaceuticals to be Acquired by AstraZeneca,...

   www.prnewswire.com › news-releases › fusion-pharmaceuticals-to-be-acquired-by-ast

   • Zapisane w pamięci cache

   19 mar 2024 · Transaction includes actinium-based clinical-stage radioconjugate targeting PSMA for prostate cancer, pipeline of radioconjugates and state-of-the-art R&D and manufacturing facilities.

7. www.investopedia.com › astrazeneca-to-buy-fusion-pharmaceuticals-for-up-to-usd2AstraZeneca to Buy Fusion Pharmaceuticals for Up to $2.4B as Firm...

   www.investopedia.com › astrazeneca-to-buy-fusion-pharmaceuticals-for-up-to-usd2

   • Zapisane w pamięci cache

   28 wrz 2024 · AstraZeneca Plc (AZN) on Tuesday said it will acquire biotech company Fusion Pharmaceuticals Inc. (FUSN) for up to $2.4 billion, expanding its pipeline of treatment for advanced prostate...